Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting.This study was to summarize our experiences in treating NS...Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting.This study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line setting.Methods:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, China.The short-term efficacies and safeties were analyzed.Results:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole group.2.There were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) months.3.There were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).4.There was no treatment-associated death and no cetuximab-associated discontinuation.The incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with chemotherapy.Conclusion:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.展开更多
目的探讨基于风险识别理念的疼痛管理联合母乳喂养对新生儿采血疼痛及采血成功率的影响,为新生儿科护士提高桡动脉采血成功率提供参考。方法选取2024年9月至2025年5月惠州市第六人民医院新生儿科收治的132例新生儿为研究对象,通过随机...目的探讨基于风险识别理念的疼痛管理联合母乳喂养对新生儿采血疼痛及采血成功率的影响,为新生儿科护士提高桡动脉采血成功率提供参考。方法选取2024年9月至2025年5月惠州市第六人民医院新生儿科收治的132例新生儿为研究对象,通过随机数字表法分为试验组(66例)和对照组(66例),对照组采用常规护理,试验组在对照组基础上采用基于风险识别理念的疼痛管理联合母乳喂养干预。比较两组采血结束后并发症发生率、首次采血成功率、疼痛面容持续时间、新生儿疼痛量表(NIPS)评分、心率及血氧饱和度。结果试验组首次采血成功率高于对照组(P<0.05);试验组采血时及采血结束后1 min NIPS评分低于对照组,疼痛面容持续时间短于对照组,差异均有统计学意义(P<0.05);试验组采血结束后1 min心率低于对照组,采血时及采血结束后1 min的血氧饱和度高于对照组(P<0.05)。结论基于风险识别理念的疼痛管理联合母乳喂养可有效缓解新生儿采血疼痛,提升采血操作成功率。展开更多
随着柔性直流电网的发展,其边界结构将发生改变,从“有边界电网”转变为“无边界电网”。如果在配置保护时,能够在原理上尽量适用于两种边界结构,则可以大大降低电网结构变化时保护验证的繁复性、提升保护应用的经济性。为提升线路行波...随着柔性直流电网的发展,其边界结构将发生改变,从“有边界电网”转变为“无边界电网”。如果在配置保护时,能够在原理上尽量适用于两种边界结构,则可以大大降低电网结构变化时保护验证的繁复性、提升保护应用的经济性。为提升线路行波保护对不同边界结构的适用性,该文提出一种新型的行波保护方案。该保护方案主要通过非故障极电流首行波积分(first current integration of non-fault pole,FCINP)实现。基于FCINP在不同边界结构电网下的距离特性和边界特性,可有效地提升保护在有边界电网和无边界电网下的故障识别性能,从而提升保护适用性。所提保护在基于PSCAD/EMTDC直流电网仿真模型中进行了性能验证。展开更多
基金Supported by a grant of Major Science and Technology Project of "National Significant New Drug Creation" (No.2008ZX09312-002)
文摘Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting.This study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line setting.Methods:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, China.The short-term efficacies and safeties were analyzed.Results:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole group.2.There were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) months.3.There were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).4.There was no treatment-associated death and no cetuximab-associated discontinuation.The incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with chemotherapy.Conclusion:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.
文摘目的探讨基于风险识别理念的疼痛管理联合母乳喂养对新生儿采血疼痛及采血成功率的影响,为新生儿科护士提高桡动脉采血成功率提供参考。方法选取2024年9月至2025年5月惠州市第六人民医院新生儿科收治的132例新生儿为研究对象,通过随机数字表法分为试验组(66例)和对照组(66例),对照组采用常规护理,试验组在对照组基础上采用基于风险识别理念的疼痛管理联合母乳喂养干预。比较两组采血结束后并发症发生率、首次采血成功率、疼痛面容持续时间、新生儿疼痛量表(NIPS)评分、心率及血氧饱和度。结果试验组首次采血成功率高于对照组(P<0.05);试验组采血时及采血结束后1 min NIPS评分低于对照组,疼痛面容持续时间短于对照组,差异均有统计学意义(P<0.05);试验组采血结束后1 min心率低于对照组,采血时及采血结束后1 min的血氧饱和度高于对照组(P<0.05)。结论基于风险识别理念的疼痛管理联合母乳喂养可有效缓解新生儿采血疼痛,提升采血操作成功率。
文摘随着柔性直流电网的发展,其边界结构将发生改变,从“有边界电网”转变为“无边界电网”。如果在配置保护时,能够在原理上尽量适用于两种边界结构,则可以大大降低电网结构变化时保护验证的繁复性、提升保护应用的经济性。为提升线路行波保护对不同边界结构的适用性,该文提出一种新型的行波保护方案。该保护方案主要通过非故障极电流首行波积分(first current integration of non-fault pole,FCINP)实现。基于FCINP在不同边界结构电网下的距离特性和边界特性,可有效地提升保护在有边界电网和无边界电网下的故障识别性能,从而提升保护适用性。所提保护在基于PSCAD/EMTDC直流电网仿真模型中进行了性能验证。
